On September 29, 2026, Pyxis Oncology, Inc. entered into an underwriting agreement for an underwritten public offering. The offering includes approximately 36 million shares of common stock and pre-funded warrants for additional shares. The transaction is set to close on October 1, 2026
Company Information
Company
Pyxis Oncology, Inc.
Location
35 Cambridgepark Drive
Boston, Massachusetts, United States
About
Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.
Fundz sees it the moment Pyxis Oncology, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.